BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 1:47:00 PM | Browse: 375 | Download: 350
Publication Name World Journal of Neurology
Manuscript ID 3608
Country/Territory United Kingdom
Received
2013-05-09 09:05
Peer-Review Started
2013-05-09 21:43
To Make the First Decision
2013-05-23 17:11
Return for Revision
2013-06-07 10:24
Revised
Second Decision
2013-10-16 09:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-10-16 10:29
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-12-19 18:58
Publish the Manuscript Online
2014-01-16 17:21
ISSN 2218-6212 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Neurosciences
Manuscript Type Frontier
Article Title Cannabinoids: Do they have the potential to treat the symptoms of multiple sclerosis?
Manuscript Source Invited Manuscript
All Author List Zubair Ahmed
Funding Agency and Grant Number
Funding Agency Grant Number
University of Birmingham
Corresponding author Dr. Zubair Ahmed, Neurotrauma and Neurodegeneration Section, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Institute of Biomedical Research (West), Edgbaston, Birmingham B15 2TT, United Kingdom. z.ahmed.1@bham.ac.uk
Keywords Multiple sclerosis; Axonal damage; Neurodegeneration; Neuroprotection
Core Tip Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and causes disability, neuropathic pain, spasticity and tremor in affected patients. Although illegal, users of cannabis report relief from pain and spasticity, probably due to the endogenous cannabinoid system that exists. cannabinoid receptor type-1 (CB1)-deficient mice accrue greater levels of neurodegeneration and poorly tolerate inflammatory and excitotoxic insults after immune attack in a model of MS, experimental allergic encephalomyelitis. Treatment of animals affected by experimental allergic uveitis (EAU) with CB1 agonists also provided significant neuroprotection from the consequences of EAU, suggesting that cannabinoids may slow down neurodegeneration in MS.
Publish Date 2014-01-16 17:21
Citation Ahmed Z. Cannabinoids: Do they have the potential to treat the symptoms of multiple sclerosis? World J Neurol 2013; 3(4): 87-96
Url http://www.wjgnet.com/2218-6212/full/v3/i4/87.htm
DOI http://dx.doi.org/10.5316/wjn.v3.i4.87
Full Article (PDF) WJN-3-87.pdf
Full Article (Word) WJN-3-87.doc
Manuscript File 3608-Review.docx
Answering Reviewers 3608-Answering reviewers.pdf
Copyright License Agreement 3608-Copyright assignment.pdf
Peer-review Report 3608-Peer review(s).pdf
Scientific Editor Work List 3608-Scientific editor work list.doc